Table 1.
Characteristics of 502 TNBC patients.
| Factor | Rate (%) | |
|---|---|---|
| Number of patients | 502 | 100 |
|
| ||
| Age at diagnosis (years) | ||
| Median | 55 | |
| Mean | 56 | |
| Range | 24–98 | |
|
| ||
| Clinical staging (cTNM) | ||
| I | 97 | 19.5 |
| II | 246 | 49 |
| III | 132 | 26 |
| IV | 27 | 5.5 |
|
| ||
| Initial clinical tumor staging | ||
| cT0 | 7 | 1 |
| cT1 | 111 | 22 |
| cT2 | 248 | 49.5 |
| cT3 | 58 | 12 |
| cT4 | 76 | 15 |
| No available data | 2 | 0.5 |
|
| ||
| Initial clinical node staging | ||
| cN0 | 243 | 48 |
| cN1 | 180 | 36 |
| cN2 | 58 | 11.5 |
| cN3 | 19 | 4 |
| No available data | 2 | 0.5 |
|
| ||
| HER2 expression | ||
| 0 or 1+ | 431 | 86 |
| 2+, FISH negative | 71 | 14 |
|
| ||
| Histological type | ||
| NST | 416 | 83 |
| Lobular | 25 | 5 |
| Medullar | 11 | 2 |
| Apocrine | 11 | 2 |
| Metaplastic | 20 | 4 |
| Others | 20 | 4 |
|
| ||
| G | ||
| 1 | 21 | 4 |
| 2 | 165 | 33 |
| 3 | 310 | 62 |
| No available data | 6 | 1 |
|
| ||
| Ki-67 expression | ||
| <14% | 140 | 28 |
| 14–30% | 183 | 36.5 |
| >30% | 133 | 26.5 |
| No available data | 46 | 9 |
|
| ||
| Vimentin expression assessed | ||
| Yes | 443 | 88 |
| No | 59 | 12 |
|
| ||
| Vimentin | ||
| Positive | 71/443 | 16 |
| Negative | 372/443 | 84 |
|
| ||
| Contralateral breast cancer | 41 | 8 |
| Other primary cancer (other than contralateral breast cancer) | 45 | 9 |
FISH: fluorescence in situ hybridization.